B D Cheson

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. ncbi request reprint New drug development in non-Hodgkin lymphomas
    B D Cheson
    National Cancer Institute, Executive Plaza North, Room 741, Bethesda, MD 20892, USA
    Curr Oncol Rep 3:250-9. 2001
  2. ncbi request reprint Rituximab: clinical development and future directions
    Bruce D Cheson
    National Cancer Institute, Executive Plaza North, Room 741, Bethesda, MD 20892, USA
    Expert Opin Biol Ther 2:97-110. 2002
  3. ncbi request reprint Bexxar (Corixa/GlaxoSmithKline)
    Bruce Cheson
    Medicine Section, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD 20892, USA
    Curr Opin Investig Drugs 3:165-70. 2002
  4. ncbi request reprint Second malignancies as a consequence of nucleoside analog therapy for chronic lymphoid leukemias
    B D Cheson
    The Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD 20892, USA
    J Clin Oncol 17:2454-60. 1999
  5. ncbi request reprint Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group
    B D Cheson
    National Cancer Institute, Bethesda, MD 20892, USA
    J Clin Oncol 17:1244. 1999
  6. ncbi request reprint Tumor lysis syndrome: an uncommon complication of fludarabine therapy of chronic lymphocytic leukemia
    B D Cheson
    Cancer Therapy Evaluation Program, Division of Cancer Diagnosis and Treatment, National Cancer Institute, Bethesda, MD 20892, USA
    J Clin Oncol 16:2313-20. 1998
  7. ncbi request reprint Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine via the Group C protocol mechanism of the National Cancer Institute: a report of 979 patients
    B D Cheson
    National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Clin Oncol 16:3007-15. 1998
  8. ncbi request reprint Report of an international working group to standardize response criteria for myelodysplastic syndromes
    B D Cheson
    National Cancer Institute, Bethesda 20892, USA
    Blood 96:3671-4. 2000
  9. ncbi request reprint The progress and promise of molecular imaging probes in oncologic drug development
    Gary J Kelloff
    Cancer Imaging Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, NIH, Bethesda, MD 20892, USA
    Clin Cancer Res 11:7967-85. 2005
  10. ncbi request reprint Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development
    Gary J Kelloff
    Cancer Imaging Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
    Clin Cancer Res 11:2785-808. 2005

Detail Information

Publications59

  1. ncbi request reprint New drug development in non-Hodgkin lymphomas
    B D Cheson
    National Cancer Institute, Executive Plaza North, Room 741, Bethesda, MD 20892, USA
    Curr Oncol Rep 3:250-9. 2001
    ..More rapid accrual to high-quality clinical studies will facilitate dissemination of new agents to patients and lead to an increased cure rate for NHL...
  2. ncbi request reprint Rituximab: clinical development and future directions
    Bruce D Cheson
    National Cancer Institute, Executive Plaza North, Room 741, Bethesda, MD 20892, USA
    Expert Opin Biol Ther 2:97-110. 2002
    ..The future promise of this antibody is a foundation on which to develop new strategies to increase the cure of patients with lymphoid malignancies...
  3. ncbi request reprint Bexxar (Corixa/GlaxoSmithKline)
    Bruce Cheson
    Medicine Section, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD 20892, USA
    Curr Opin Investig Drugs 3:165-70. 2002
    ..In February 2001, ABN Amro Predicted launch in 2001 and sales of US $25 million rising to US $70 million in 2003 [422363]. Corixa and GlaxoSmithKline anticipate a launch in the US in 2002 [424619]...
  4. ncbi request reprint Second malignancies as a consequence of nucleoside analog therapy for chronic lymphoid leukemias
    B D Cheson
    The Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD 20892, USA
    J Clin Oncol 17:2454-60. 1999
    ..The purpose of the present study was to assess the frequency of second tumors in patients with CLL who are treated with fludarabine and in patients with HCL who are treated with DCF and CdA...
  5. ncbi request reprint Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group
    B D Cheson
    National Cancer Institute, Bethesda, MD 20892, USA
    J Clin Oncol 17:1244. 1999
    ..We hope that these guidelines will serve to improve communication among investigators and comparability among clinical trials until clinically relevant laboratory and imaging studies are identified and become more widely available...
  6. ncbi request reprint Tumor lysis syndrome: an uncommon complication of fludarabine therapy of chronic lymphocytic leukemia
    B D Cheson
    Cancer Therapy Evaluation Program, Division of Cancer Diagnosis and Treatment, National Cancer Institute, Bethesda, MD 20892, USA
    J Clin Oncol 16:2313-20. 1998
    ..To quantify the incidence and severity of tumor lysis syndrome (TLS) as a consequence of fludarabine therapy in patients with advanced chronic lymphocytic leukemia (CLL)...
  7. ncbi request reprint Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine via the Group C protocol mechanism of the National Cancer Institute: a report of 979 patients
    B D Cheson
    National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Clin Oncol 16:3007-15. 1998
    ..To provide cladribine (CdA) to physicians for the treatment of patients with previously treated or untreated hairy cell leukemia (HCL), and to determine the response rate, response duration, survival, and toxicity with this agent...
  8. ncbi request reprint Report of an international working group to standardize response criteria for myelodysplastic syndromes
    B D Cheson
    National Cancer Institute, Bethesda 20892, USA
    Blood 96:3671-4. 2000
    ..Until then, it is hoped these guidelines will serve to improve communication among investigators and to ensure comparability among clinical trials. (Blood. 2000;96:3671-3674)..
  9. ncbi request reprint The progress and promise of molecular imaging probes in oncologic drug development
    Gary J Kelloff
    Cancer Imaging Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, NIH, Bethesda, MD 20892, USA
    Clin Cancer Res 11:7967-85. 2005
    ..The current regulatory opportunities for new and existing probe development and testing are also reviewed, with a focus on recent Food and Drug Administration guidance to facilitate early clinical development of promising probes...
  10. ncbi request reprint Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development
    Gary J Kelloff
    Cancer Imaging Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
    Clin Cancer Res 11:2785-808. 2005
    ....
  11. ncbi request reprint Pentostatin in hairy cell leukemia: treatment by the special exception mechanism
    J L Grem
    Investigational Drug Branch, National Cancer Institute, Bethesda, MD 20892
    J Natl Cancer Inst 81:448-53. 1989
    ..The experience gained with these patients supplements the information presently being collected from the controlled clinical trials and supports the development of a group C treatment protocol...
  12. ncbi request reprint The role of FDG-PET scans in patients with lymphoma
    Pamela Seam
    National Cancer Institute, Bethesda, MD, USA
    Blood 110:3507-16. 2007
    ..Recent attempts to standardize PET in clinical trials and incorporation of this technology into uniformly adopted response criteria will hopefully lead to improved outcome for patients with lymphoma...
  13. ncbi request reprint Phase II and dose-escalation with or without granulocyte colony-stimulating factor study of 9-aminocamptothecin in relapsed and refractory lymphomas
    W H Wilson
    Medicine Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Clin Oncol 16:2345-51. 1998
    ..To assess the efficacy and maximum dose-intensity of a new topoisomerase I (topo I)-targeting agent, 9-aminocamptothecin (9-AC), in patients with relapsed or refractory lymphomas...
  14. ncbi request reprint Rituximab treatment of refractory fludarabine-associated immune thrombocytopenia in chronic lymphocytic leukemia
    Upendra P Hegde
    Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    Blood 100:2260-2. 2002
    ..These results suggest rituximab can rapidly reverse refractory fludarabine-associated ITP...
  15. ncbi request reprint Hematologic malignancies: new developments and future treatments
    Bruce D Cheson
    Clinical Investigations Branch, National Cancer Institute, Bethesda, MD, USA
    Semin Oncol 29:33-45. 2002
    ..Future therapeutic strategies should involve rational combinations of new chemotherapy drugs, biologic agents, and antisense compounds to increase the cure rate in patients with lymphoma...
  16. ncbi request reprint Clinical trials referral resource. Current clinical trials of R115777 (Zarnestra)
    John J Wright
    National Cancer Institute, USA
    Oncology (Williston Park) 16:930-1, 935-7. 2002
  17. ncbi request reprint Clinical trials referral resource. Current clinical trials of molecularly targeted agents in children with cancer
    Malcolm A Smith
    National Cancer Institute, USA
    Oncology (Williston Park) 16:328, 331-3, 338 passim. 2002
  18. ncbi request reprint Positron-emission tomography and assessment of cancer therapy
    Malik E Juweid
    Department of Radiology and the Holden Comprehensive Cancer Center, University of Iowa, Iowa City 52242, USA
    N Engl J Med 354:496-507. 2006
  19. ncbi request reprint Emerging treatments for indolent lymphoma
    Bruce D Cheson
    Georgetown University Hospital, Lombardi Comprehensive Cancer Center, Washington, DC 20057, USA
    Clin Adv Hematol Oncol 5:1-9; quiz 11-2. 2007
    ..Other emerging therapeutics include new chemotherapeutics, small-molecule and monoclonal antibodies, radioimmunotherapy, apoptosis-inducing agents, and immunomodulators...
  20. ncbi request reprint Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography
    Malik E Juweid
    Department of Radiology, Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA 52242, USA
    J Clin Oncol 23:4652-61. 2005
    ....
  21. ncbi request reprint Revised response criteria for malignant lymphoma
    Bruce D Cheson
    Division of Hematology Oncology, Georgetown University Hospital, Washington, DC, USA
    J Clin Oncol 25:579-86. 2007
    ..Standardized response criteria are needed to interpret and compare clinical trials and for approval of new therapeutic agents by regulatory agencies...
  22. ncbi request reprint Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma
    Malik E Juweid
    Department of Radiology, University of Iowa, Iowa City, IA 52242, USA
    J Clin Oncol 25:571-8. 2007
    ..To develop guidelines for performing and interpreting positron emission tomography (PET) imaging for treatment assessment in patients with lymphoma both in clinical practice and in clinical trials...
  23. doi request reprint Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study
    Jonathan W Friedberg
    James P Wilmot Cancer Center, University of Rochester, 601 Elmwood Ave, Box 704, Rochester, NY, 14642, USA
    J Clin Oncol 26:204-10. 2008
    ..This phase II multicenter study evaluated the efficacy and toxicity of bendamustine in patients with B-cell non-Hodgkin's lymphoma (NHL) refractory to rituximab...
  24. ncbi request reprint Pre- and post-treatment evaluation of non-Hodgkin's lymphoma
    Blanche H Mavromatis
    Georgetown University Medical Center, Washington, DC, USA
    Best Pract Res Clin Haematol 15:429-47. 2002
    ....
  25. ncbi request reprint Prolonged follow-up after initial therapy with 2-chlorodeoxyadenosine in patients with indolent non-Hodgkin lymphoma: results of Cancer and Leukemia Group B Study 9153
    Kristie A Blum
    Division of Hematology Oncology, Department of Internal Medicine, The Ohio State University, Columbus, Ohio 43210, USA
    Cancer 107:2817-25. 2006
    ..The objective of this study was to determine the efficacy and toxicity of 2-chlorodeoxyadenosine (2-CdA) in patients with untreated, indolent non-Hodgkin lymphoma (NHL)...
  26. ncbi request reprint Mantle cell lymphoma: clinicopathologic features and treatments
    John Kauh
    Lombardi Cancer Center, Georgetown University Hospital, Washington, DC, USA
    Oncology (Williston Park) 17:879-91, 896; discussion 896-8. 2003
    ....
  27. doi request reprint New staging and response criteria for non-Hodgkin lymphoma and Hodgkin lymphoma
    Bruce D Cheson
    Georgetown University Hospital, Lombardi Comprehensive Cancer Center, 3800 Reservoir Road Northwest, Washington, DC 20007, USA
    Radiol Clin North Am 46:213-23, vii. 2008
    ....
  28. ncbi request reprint Radioimmunotherapy of non-Hodgkin lymphomas
    Bruce D Cheson
    Georgetown University Hospital, Lombardi Cancer Center, Washington, DC 20007, USA
    Blood 101:391-8. 2003
    ..Ongoing clinical trials are attempting to better characterize the role of these promising agents...
  29. doi request reprint Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma
    Bruce D Cheson
    Division of Hematology Oncology, Georgetown University Hospital, Washington, DC 20007, USA
    N Engl J Med 359:613-26. 2008
  30. doi request reprint Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma
    K Sue Robinson
    QE II Health Sciences Centre, Halifax, Nova Scotia, Canada
    J Clin Oncol 26:4473-9. 2008
    ..This study evaluated bendamustine plus rituximab in 67 adults with relapsed, indolent B-cell or mantle cell lymphoma without documented resistance to prior rituximab...
  31. ncbi request reprint Results of a phase II study of 506U78 in cutaneous T-cell lymphoma and peripheral T-cell lymphoma: CALGB 59901
    Myron S Czuczman
    Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    Leuk Lymphoma 48:97-103. 2007
    ..Median event-free survival was 1.2 months and median overall survival was 3 months. Due to lack of efficacy and excessive toxicity, nelarabine is not recommended as monotherapy in adult patients with CTCL and STCL at this dose schedule...
  32. ncbi request reprint Overcoming mechanisms of RECISTance in lymphoma
    Bruce D Cheson
    Georgetown University Hospital, Washington, DC 20007, USA
    Leuk Lymphoma 48:447-8. 2007
  33. ncbi request reprint Single agent bortezomib in the treatment of relapsed and refractory Hodgkin lymphoma: cancer and leukemia Group B protocol 50206
    Kristie A Blum
    Division of Hematology Oncology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA
    Leuk Lymphoma 48:1313-9. 2007
    ..Grade 3 - 4 adverse events, primarily thrombocytopenia, occurred in 15 patients. Therefore, although well tolerated, 1.3 mg/m(2) bortezomib administered biweekly has no single agent activity in relapsed/refractory classical HL...
  34. doi request reprint Thalidomide has limited single-agent activity in relapsed or refractory indolent non-Hodgkin lymphomas: a phase II trial of the Cancer and Leukemia Group B
    Sonali M Smith
    The University of Chicago, Chicago, IL 60637, USA
    Br J Haematol 140:313-9. 2008
    ..Our results failed to demonstrate an important response rate to single agent thalidomide in indolent lymphomas and contrast with the higher activity level reported with the second generation immunomodulatory agent, lenalidomide...
  35. ncbi request reprint Recent developments in the treatment of CLL
    Bruce D Cheson
    Clin Adv Hematol Oncol 6:6-8; quiz 10-2. 2008
  36. ncbi request reprint Although many of the items are natural products, we do not know what harm they might cause in the often excessive quantities that are recommended
    Bruce D Cheson
    Clin Adv Hematol Oncol 5:499. 2007
  37. ncbi request reprint The International Harmonization Project for response criteria in lymphoma clinical trials
    Bruce D Cheson
    Georgetown University Hospital, 3800 Reservoir Road, NW, Washington, DC 20007, USA
    Hematol Oncol Clin North Am 21:841-54. 2007
    ..Modifications of these recommendations are expected as new information and improved technologies become available...
  38. ncbi request reprint Clinical management of T-cell malignancies: current perspectives, key issues, and emerging therapies
    Bruce D Cheson
    Georgetown University Hospital, Lombardi Comprehensive Cancer Center, Washington, DC 20007, USA
    Semin Oncol 34:S3-7. 2007
    ....
  39. ncbi request reprint Clinical cancer advances 2007: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology
    Julie Gralow
    American Society of Clinical Oncology, 1900 Duke St, Suite 200, Alexandria, VA 22314, USA
    J Clin Oncol 26:313-25. 2008
    ..I hope you find it useful. Sincerely, Nancy E. Davidson, MD President American Society of Clinical Oncology...
  40. doi request reprint Lenalidomide for the treatment of B-cell malignancies
    Asher A Chanan-Khan
    Roswell Park Cancer Institute, Buffalo, NY, USA
    J Clin Oncol 26:1544-52. 2008
    ..This review summarizes the data from various clinical investigations and highlights the impact of lenalidomide in the management of patients with B-cell malignancies...
  41. ncbi request reprint Radioimmunotherapy of non-Hodgkin's lymphomas
    Bruce D Cheson
    Georgetown University Hospital, Lombardi Comprehensive Cancer Center, 3800 Reservoir Rd, N W, Washington, DC 20007, USA
    Curr Drug Targets 7:1293-300. 2006
    ..Hopefully, the rational development of RIT will lead to a prolongation of survival for patients with NHL...
  42. ncbi request reprint Clinical trials referral resource. Current clinical trials in non-Hodgkin's lymphoma
    Bruce D Cheson
    National Cancer Institute, USA
    Oncology (Williston Park) 16:762-3, 766. 2002
  43. ncbi request reprint Bendamustine in the treatment of hematologic malignancies. Introduction
    Volker Diehl
    Department of Internal Medicine, University Hospital, Cologne, Germany
    Semin Oncol 29:1-3. 2002
  44. ncbi request reprint Monoclonal antibody therapy of chronic lymphocytic leukemia
    Blanche Mavromatis
    Department of Hematology Oncology, Lombardi Cancer Center, Georgetown University Hospital, 3800 Reservoir Rd, N W, Washington, DC, USA
    J Clin Oncol 21:1874-81. 2003
    ..It is hoped that the rational development of combinations of the various promising antibodies with chemotherapy and each other will lead to more effective approaches for patients with CLL...
  45. ncbi request reprint Oral fludarabine: a viewpoint by Bruce D. Cheson
    Bruce D Cheson
    Lombardi Cancer Center, Georgetown University, Washington, DC, USA
    Drugs 63:2325. 2003
  46. ncbi request reprint Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia
    Bruce D Cheson
    Department of Hematology Oncology, Georgetown University, Lombardi Cancer Center, 3800 Reservoir Rd, NW, Washington, DC 20007, USA
    J Clin Oncol 21:4642-9. 2003
    ..Storage of viable blasts for correlative studies is important for future progress in the therapy of these disorders...
  47. ncbi request reprint Novel therapies for chronic lymphocytic leukemia
    Blanche H Mavromatis
    Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC 20057, USA
    Blood Rev 18:137-48. 2004
    ..The mechanism of action of the new drugs and their role in CLL, as well as the emergence of new prognostic markers are discussed...
  48. ncbi request reprint What is new in lymphoma?
    Bruce D Cheson
    Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA
    CA Cancer J Clin 54:260-72. 2004
    ....
  49. ncbi request reprint Monoclonal gammopathy in extranodal marginal zone lymphoma (ENMZL) correlates with advanced disease and bone marrow involvement
    Ekatherine Asatiani
    Georgetown University Hospital, Departments of Oncology and Medicine, Lombardi Comprehensive Cancer Center, Washington, DC 20007, USA
    Am J Hematol 77:144-6. 2004
    ..0007). Prevalence of monoclonal gammopathy is higher than previously recognized and indicates advanced disease. However, the prognostic significance of the presence of monoclonal gammopathy in this population is unknown...
  50. ncbi request reprint Managing malignancy-associated hyperuricemia with rasburicase
    Bruce D Cheson
    Georgetown University, Lombardi Comprehensive Cancer, Center, Washington, DC 20007, USA
    J Support Oncol 3:117-24. 2005
    ..Current and future trials will evaluate alternate doses and schedules of rasburicase to maintain its efficacy while reducing its cost...
  51. ncbi request reprint Role of positron emission tomography in lymphoma
    Malik E Juweid
    J Clin Oncol 23:4577-80. 2005
  52. ncbi request reprint Individualizing therapy for the hematologic malignancies: the stuff of genes and dreams
    Bruce D Cheson
    J Clin Oncol 23:6283-4. 2005
  53. ncbi request reprint Monoclonal antibody therapy of chronic lymphocytic leukemia
    Bruce D Cheson
    Lombardi Comprehensive Cancer Center, Georgetown University Hospital, 3800 Reservoir Rd, NW, Washington, DC, USA
    Cancer Immunol Immunother 55:188-96. 2006
    ..The rational development of combinations of these promising approaches may eliminate the need for chemotherapy, leading to safer and more effective approaches for patients with CLL...
  54. ncbi request reprint The role of radioimmunotherapy with yttrium-90 ibritumomab tiuxetan in the treatment of non-Hodgkin lymphoma
    Bruce D Cheson
    Lombardi Comprehensive Cancer Center, Georgetown University Hospital, Washington, DC 20007, USA
    BioDrugs 19:309-22. 2005
    ....
  55. ncbi request reprint Monoclonal antibody therapy for B-cell malignancies
    Bruce D Cheson
    Department of Hematology, Georgetown University Hospital, Lombardi Comprehensive Cancer Center, Washington, DC 20007, USA
    Semin Oncol 33:S2-14. 2006
    ..New treatment regimens, including combinations of monoclonal antibodies, could enhance complete response rates and prolong progression-free survival, perhaps eventually improving our ability to cure patients with lymphoid malignancies...
  56. ncbi request reprint The cancer and leukemia group B lymphoma committee
    Bruce D Cheson
    Georgetown University Hospital, Washington, District of Columbia and Dana Farber Cancer Institute, Boston, Massachusetts, USA
    Clin Cancer Res 12:3572s-5s. 2006
    ..The Cancer and Leukemia Group B (CALGB) Lymphoma Committee highlight below clinical trials that have resulted in improved patient outcome for the more frequent lymphoma subtypes...
  57. ncbi request reprint An oncoethical issue
    Bruce D Cheson
    Clin Adv Hematol Oncol 4:241. 2006
  58. ncbi request reprint Sequential doxorubicin and topotecan in relapsed/refractory aggressive non-Hodgkin's lymphoma: results of CALGB 59906
    Sonali M Smith
    University of Chicago, Chicago, IL 60637, USA
    Leuk Lymphoma 47:1511-7. 2006
    ..The activity in Burkitt's lymphoma should be investigated further...
  59. ncbi request reprint CHOP plus rituximab--balancing facts and opinion
    Bruce D Cheson
    N Engl J Med 346:280-2. 2002